Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth

Cancer Biology and Therapy

Volumn 2, Issue 1, 2003, Pages 49-53

  Liby, Karen ^a   Neltner, Bonnie ^a   Mohamet, Lisa ^a   Burd, Craig ^a   Ben Jonathan, Nira ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Breast cancer; Endostatin; Tumor growth

Indexed keywords

EID: 79960750659     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.179     Document Type: Article

References (34)

1. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 1984; 49:405-13. (Pubitemid 14125248)
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64. (Pubitemid 26272076)
3. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002; 99:10730-5.
4. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21:505-15. (Pubitemid 30137936)
5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
6. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
7. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996; 167-90.
8. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-85. (Pubitemid 28015876)
9. Blezinger P, Wang J, Gondo M, Quezeda A, Meherns D, French M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature Biotech 1999; 17:343-8. (Pubitemid 29166035)
10. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999; 59:6251-6. (Pubitemid 30035650)
11. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A 2000; 97:4802-7. (Pubitemid 30238638)
12. Boehm T, Folkman J, Browder T, O'Reilly M. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-7.
13. Eisterer W, Jiang X, Bachelot T, Pawliuk R, Abramovich C, Leboulch P, et al. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther 2002; 5:352-9. (Pubitemid 34308659)
14. Pawliuk R, Bachelot T, Zurkiya O, Eriksson A, Cao Y, Leboulch P. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol Ther 2002; 5:345-51. (Pubitemid 34308658)
15. Jouanneau E, Alberti L, Nejjari M, Treilleux I, Vilgrain I, Duc A, et al. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J Neurooncol 2001; 51:11-8. (Pubitemid 32321896)
16. Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev 2000; 19:181-90. (Pubitemid 32004708)
17. Chen QR, Kumar D, Stass SA, Mixson AJ. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999; 59:3308-12. (Pubitemid 29334481)
18. Baillie CT, Winslet MC, Bradley NJ. Tumor vasculature - a potential therapuetic target. Br J Cancer 1995; 72:257-67.
19. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001; 19:45S-51S.
20. Thompson WD, Li WW, Maragoudakis M. The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies. J Pathol 2000; 190:330-7. (Pubitemid 30141378)
21. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20:3792-803.
22. Eder JP, Jr., Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20:3772-84.
23. Jung YD, Ahmad SA, Akagi Y, Takahashi Y, Liu W, Reinmuth N, et al. Role of the tumor microenvironment in mediating response to anti- angiogenic therapy. Cancer Metastasis Rev 2000; 19:147-57. (Pubitemid 32004704)
24. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60:1388-93. (Pubitemid 30152012)
25. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 2001; 98:4605-10. (Pubitemid 32295023)
26. Cohen J. Behind the headlines of endostatin's ups and downs. Science 1999; 283:1250-1. (Pubitemid 29108969)
27. Greco O, Scott SD, Marples B, Dachs GU. Cancer gene therapy: 'delivery, delivery, delivery'. Front Biosci 2002; 7:1516-24.
28. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274:11721-6.
29. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000; 60:1503-6. (Pubitemid 30183414)
30. MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR, et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001; 276:25190-6.
31. Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001; 7:811-22. (Pubitemid 32436441)
32. Hanai J, Gloy J, Karumanchi SA, Kale S, Tang J, Hu G, et al. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 2002; 158:529-39. (Pubitemid 34851711)
33. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 1999; 59:6052-6. (Pubitemid 30035619)
34. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19:1187-94. (Pubitemid 30151015)